Edesa Biotech, Inc. (EDSA)

USD 1.82

(-2.67%)

Market Cap (In USD)

6.31 Million

Revenue (In USD)

-

Net Income (In USD)

-8.37 Million

Avg. Volume

7607.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.69-5.99
PE
-
EPS
-
Beta Value
0.838
ISIN
CA27966L3065
CUSIP
27966L108
CIK
1540159
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Pardeep Nijhawan FRCPC, M.D.
Employee Count
-
Website
https://www.edesabiotech.com
Ipo Date
2010-06-21
Details
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.